These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Glucocorticoids combined with tofacitinib in the treatment of Castleman's disease: A case report.
    Author: Liu XR, Tian M.
    Journal: World J Clin Cases; 2022 Oct 16; 10(29):10794-10802. PubMed ID: 36312499.
    Abstract:
    BACKGROUND: Castleman's disease (CD), also known as vascular follicular lymphadenopathy is a rare proliferative disease of lymphoid tissue of unknown etiology that is clinically classified as unicentric CD (UCD) or multicentric CD (MCD) depending on lymph node involvement. At present, idiopathic MCD (iMCD) is treated with interleukin-6 inhibitors, but some patients have poor clinical outcomes. This paper reports on a case of iMCD that achieved a good therapeutic effect after treatment with glucocorticoids combined with tofacitinib. The relevant data are summarized and reported below. CASE SUMMARY: This paper reports on a case of MCD in a 49-year-old female with persistent peritoneal effusion as the first manifestation and combined with multiple lymphadenopathies. Lymph node biopsy showed Castleman's disease-like changes. The ascites subsided after treatment with glucocorticoids and tofacitinib, indicating that the treatment was effective. CONCLUSION: The combination of glucocorticoids with tofacitinib is an effective regimen for the treatment of CD.
    [Abstract] [Full Text] [Related] [New Search]